survodutide vs retatrutide

updated September 11, 2026

survodutide (tier A) vs retatrutide (tier S): what each is, why each got its grade, half-life and source counts side by side.

survodutide · tier A

Investigational GLP-1/glucagon dual agonist. In a phase 3 obesity trial, mean weight loss was 13.0% versus 5.4% with placebo at 76 weeks. Separate trials studied MASH and liver fibrosis.

tier rationale

survodutide has a published phase 3 obesity result (SYNCHRONIZE-1: about 16.6% weight loss over 76 weeks) and a phase 2 MASH signal strong enough to earn FDA Breakthrough Therapy designation. that is real, late-stage clinical evidence, which puts it firmly in A territory. it lands below retatrutide (S, deeper phase 3 weight loss) because the obesity number is more modest and it remains investigational with no approval and confirmatory MASH outcomes still years out. graded on merit: strong data, narrow no-label status.

retatrutide · tier S

the most potent weight loss drug ever tested. 24.2% in phase 2, then 28.3% in TRIUMPH-1 phase 3, 30.3% at two years. not approved yet.

tier rationale

now that the pivotal phase 3 obesity trial has read out (TRIUMPH-1: 28.3% weight loss at 12mg over 80 weeks, 30.3% at two years), reta has the strongest published obesity-drug efficacy in the catalog. Bariatric-surgery territory from a weekly shot. triple receptor mechanism adds glucagon agonism on top of tirz's dual mechanism, which pushes lipolysis and energy expenditure. S-tier based on phase 3 efficacy, but with meaningful open questions on safety and no announced approval date.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.